TAVR for Aortic Valve Disease
Transcatheter Aortic Valve Replacement for Severe Aortic Valve Disease: Multi-center, Real-word Registry
Nanjing First Hospital, Nanjing Medical University
5,000 participants
Jul 1, 2022
OBSERVATIONAL
Conditions
Summary
Transcatheter aortic valve replacement (TAVR) has became an important treatment of severe aortic stenosis (AS). Several randomized clinical trials showed that TAVR was non-inferior or superior to surgical aortic valve replacement (SAVR). However, many different issues have emerged: TAVR in younger patients? valve leaflet thrombosis? transcatheter valve durability? coronary reaccess after TAVR? TAVR in bicuspid aortic valve? TAVR in aortic regurgitation? etc. Hence, a prospective, multicenter database is created to provide the real-word data for these questions.
Eligibility
Inclusion Criteria2
- Clinical diagnosis of severe aortic stenosis or aortic regurgitation
- Patients undergo transcatheter aortic valve replacement
Exclusion Criteria1
- patients refuse the clinical follow-up
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
patients with severe aortic valve disease underwent transcatheter heart valve
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05439863